Log in

256940 Keeps Biopharma Inc. KRX · South Korea

Keeps Biopharma (256940) news

Keeps Biopharma Inc. is a public biotech or pharmaceutical company listed on KRX under the ticker 256940, recorded under South Korea. The directory classifies it as Biotechnology / therapeutics. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Keeps Biopharma news

We have not published a story on Keeps Biopharma yet. When there is news, it will appear here.

Questions about Keeps Biopharma

What is the ticker symbol of Keeps Biopharma?

Keeps Biopharma Inc. trades under the ticker 256940 on KRX.

Where is Keeps Biopharma listed?

Keeps Biopharma Inc. is listed on KRX.

Which country or territory is Keeps Biopharma listed under?

Our directory records Keeps Biopharma Inc. under South Korea.

What does Keeps Biopharma do?

Our directory classifies Keeps Biopharma Inc. as: Biotechnology / therapeutics. This is a directory classification, not a description of the pipeline.

What is the ISIN of Keeps Biopharma?

The ISIN recorded for Keeps Biopharma Inc. is KR7256940008.

Does aibio.space cover Keeps Biopharma?

aibio.space lists Keeps Biopharma Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Keeps Biopharma?

Companies in our directory listed in the same country and business area as Keeps Biopharma: Penetrium Bioscience, HLB Therapeutics Co., CHA Biotech Co., S.Biomedics Co., CJ Bioscience., Ensol Biosciences.

Investor discussion: Keeps Biopharma

Members talk about Keeps Biopharma (256940). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open KRX:256940 on TradingView.

Listing details

Keeps Biopharma Inc. is a public biotech or pharmaceutical company listed on KRX under the ticker 256940, recorded under South Korea. The directory classifies it as Biotechnology / therapeutics. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Keeps Biopharma Inc.
Ticker
256940
Listing
KRX
Country or territory
South Korea
Business scope
Biotechnology / therapeutics
ISIN
KR7256940008
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.